DYNAPAR contains Diclofenac which belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) which reduces pain and inflammation. It is used to treat mild to moderate and severe painful conditions such as flare ups of joint or back pain, attacks of gout, pain caused by kidney stones, injuries, fractures or trauma. It is also used in hospital settings to prevent or treat pain following an operation.
Diclofenac is a NSAID which exhibits anti-inflammatory analgesic and antipyretic activities. It involves inhibition of cyclooxygenase (COX-1 and COX-2) and it is a potent inhibitor of prostaglandin synthesis in vitro. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain and mediators of inflammation. Diclofenac is an inhibitor of prostaglandin synthesis; its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
Before receiving this medicine, tell your doctor if you have liver, kidney or heart problems, are pregnant or breastfeeding. It is not suitable for use in children and adolescents below 18 years of age. The common side effects are pain, redness, burning at the injection site.
Treats,
DYNAPAR works by blocking the action of enzyme cyclooxygenase, which is required for the biosynthesis of prostaglandins.
DYNAPAR should be only given by a doctor or nurse. Your healthcare provider will administer the right dose.
DYNAPAR is not recommended for use more than 6 months pregnancy unless necessary. Discuss the risks and benefits with your doctor.
DYNAPAR should be used with caution during breastfeeding unless necessary. Discuss the risks and benefits with your doctor.
Do not drive or handle any machines while taking this medicine as it may cause dizziness, tiredness, sleepiness or blurred vision.
DYNAPAR is not recommended in patients with severe kidney failure or any active kidney diseases. Discuss the risks and benefits with your doctor.
DYNAPAR is not recommended in patients with liver failure or any other active liver diseases. Discuss the risks and benefits with your doctor.
Tell your doctor if you are allergic (hypersensitive) to Diclofenac.
DYNAPAR is not recommended in patients with severe heart failure, cerebrovascular disease or any other active heart diseases. Discuss the risks and benefits with your doctor.
Inform your doctor if you have or had,
Inform your doctor if you are using or have recently taken any other medicines, including medicines obtained without a prescription or the following,
Drug | : | Diclofenac |
Pharmacological Category | : | Analgesic, Nonopioid, Nonsteroidal Anti-inflammatory Drug (NSAID) |
Therapeutic Indication | : | Management of mild to moderate pain & moderate to severe pain |
Dosage Forms | : | Capsule, Tablet, Injection, Oral solution |
Store below 20-25°C and keep out of reach of children.
Can DYNAPAR be used during pregnancy?
It is not recommended during the last 3 months of pregnancy as it may cause harmful effects on baby. It may be prescribed in pregnant women only if the benefits outweigh the risks involved with its use in pregnant women.
Is DYNAPAR safe?
Yes, it is safe if administered by your doctor. However, tell your doctor if you have any heart diseases, because it may raise the risk of heart and blood vessel problems.
Can DYNAPAR administer for children?
It is not suitable for use in children and adolescents under 18 years of age.
1. Furst DE, Ulrich RW, Varkey-Altamirano C. Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Antirheumatic Drugs, Nonopioids Analgesics, & Drugs Used in Gout. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. Page: 626.
2. Grosser T, Smyth E, FitzGerald GA. Anti-Inflammatory, Antipyretic, and Analgesic Agents; Pharmacotherapy of Gout. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. Page: 986-987.
3. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page:295-297.
4. Jun Yeol Lee, Jun Hwi Cho, Myoung Cheol Shin, Taek Geun Ohk, Hui Young Lee and Chan Woo Park. Single intramuscular injection of diclofenac sodium in febrile pediatric patients: Indian journal of pharmacology. May- June 2015; [Accessed on Jan 21, 2021]
5. Flynn Pharma Ltd. IBSA Farmaceutici Italia Srl, Electronic Medicines Compendium (EMC); [Revised on Sep 28, 2020] [Accessed on Jan 21, 2021] https://www.medicines.org.uk/emc/files/pil.9399.pdf
6. Hospira, Inc., (USA). 1988, U.S. Food & Drug Administration; [Revised on Dec, 2014] [Accessed on Jan 21, 2021] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022396lbl.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.